Synopsis

ICD Research's Novo Nordisk A/S .: Company Profile and SWOT Analysis contains in depth information and data about the company and its operations. The profile contains a company overview, business description, competitive benchmarking, SWOT analysis, key facts, information on products and services, details of locations and subsidiaries, plus information on key news events affecting the company.

Summary

ICD Research's Novo Nordisk A/S .: Company Profile and SWOT Analysis is a crucial resource for industry executives and anyone looking to access key information about Novo Nordisk A/S.

ICD Research's Novo Nordisk A/S .: Company Profile and SWOT Analysis report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. ICD Research strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report.

Scope

• Examines and identifies key information and issues about Novo Nordisk A/S for business intelligence requirements.
• Studies and presents the company's strengths, weaknesses, opportunities (growth potential) and threats (competition). Strategic and operational business information is objectively reported.
• Provides data on company financial performance and competitive benchmarking.
• The profile also contains information on business operations, company history, major products and services, prospects, key employees, locations and subsidiaries.

Reasons To Buy

• Quickly enhance your understanding of Novo Nordisk A/S.
• Gain insight into the marketplace and a better understanding of internal and external factors which could impact the industry.
• Increase business/sales activities by understanding your competitors’ businesses better.
• Recognize potential partnerships and suppliers.

Key Highlights

Novo Nordisk A/S (Novo Nordisk) is a leading provider of diabetic care products across the world. The company also maintains leading positions within growth hormone therapy, haemophilia care, and hormone replacement therapy. Novo Nordisk discovers, develops, manufactures, and markets pharmaceutical products and services for patients, medical professionals and society. The company classifies its operations under two segments - Diabetes care and Biopharmaceuticals. It has a network of subsidiaries, affiliates, and offices in 74 countries, and markets its products in over 180 countries across the world. Novo Nordisk is headquartered in Bagsvaerd, Denmark.
 

1 Business Analysis
1.1 Company Overview
1.2 Business Description
1.3 Major Products and Services
2 Analysis of Key Performance Indicators
2.1 Five Year Snapshot: Overview of Financial and Operational Performance Indicators
2.2 Key Financial Performance Indicators
2.2.1 Revenue and Operating Profit
2.2.2 Asset, Liabilities and Capex
2.2.3 Net Debt vs. Gearing Ratio
2.2.4 Operational Efficiency
2.2.5 Solvency
2.2.6 Valuation
2.3 Competitive benchmarking
2.3.1 Market Capitalization
2.3.2 Efficiency
2.3.3 Capital Expenditure
2.3.4 Turnover – Inventory and Asset
2.3.5 Liquidity
3 Mergers & Acquisitions and Partnerships
3.1 M&A and Partnerships Strategy
4 recent Developments
5 SWOT Analysis
5.1 SWOT Analysis - Overview
5.2 Strengths
5.3 Weaknesses
5.4 Opportunities
5.5 Threats
6 Company Statement
7 history
8 Key employees
9 Key employee Biographies
10 locations and Subsidiaries
10.1 Head Office
10.2 Other locations and Subsidiaries
11 Appendix
11.1 Methodology
11.2 Ratio Definitions
11.3 Disclaimer

List of Tables

Table 1: Major Products and Services
Table 2: Key Ratios - Annual
Table 3: Key Ratios - Interim
Table 4: Key Capital Market Indicators
Table 5: History
Table 6: Key Employees
Table 7: Key Employee Biographies
Table 8: Subsidiaries
Table 9: Locations

List of Figures

Figure 1: Revenue and Operating Profit
Figure 2: Financial Position
Figure 3: Net Debt vs. Gearing Ratio
Figure 4: Operational Efficiency
Figure 5: Solvency
Figure 6: Valuation
Figure 7: Market Capitalization
Figure 8: Efficiency
Figure 9: Capital Expenditure
Figure 10: Turnover – Inventory and Asset
Figure 11: Liquidity